Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMF + Glucocorticoid in IgG4-Related Disease
NCT06663618Recruiting
- Start
- Sep 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mycophenolate mofetil in IgG4-related disease (IgG4-RD) (2 arms). Primary endpoint: Recurrence rate of IgG4-RD at 72 weeks. Started Sep 2023; status: recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT06663618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06663618.